Michael AragonChief Medical Officer

Michael Aragon

Chief Medical Officer

Michael Aragon joined Outset as Chief Medical Officer in September 2018, after 14 years of clinical practice as a founding partner and President of North Texas Kidney Consultants- DFW. He is board certified in Internal Medicine and Nephrology, receiving his training at the University of Texas Health Sciences Center in Houston. His clinical research focus has been on the expansion and improvement of home dialysis options for patients with renal disease.

Michael received his undergraduate degree from Texas A&M University, and his medical degree from The University of Texas Medical School.

INDICATIONS FOR USE:

The Tablo^® Hemodialysis System and TabloCart™ is indicated for use in patients with acute and/or chronic renal failure, with or without ultrafiltration, in an acute or chronic care facility. Treatments must be administered under physician’s prescription and observed by a trained individual who is considered competent in the use of the device. The Tablo Hemodialysis System is also indicated for use in the home. Treatment types available include Intermittent Hemodialysis (IHD), Sustained Low Efficiency Dialysis (SLED/ SLEDD), Prolonged Intermittent Renal Replacement Therapy (PIRRT), and Isolated Ultrafiltration.

This device is not indicated for continuous renal replacement therapy (CRRT) and is cleared for use for up to 24 hours. The dialysate generated by this device is not sterile and should not be used for intravenous (IV) infusion.

2214-v2

Tablo

Patients

Healthcare providers